Overview
Biopharmaceutical firm's fiscal Q4 revenue rose slightly yr/yr
Company reported a net loss for Q4, widening from the previous year
Initiated DAYBreak pivotal Phase 2 study for bexobrutideg in relapsed/refractory CLL
Outlook
Company plans Phase 3 trial for DAYBreak CLL-306 in first half of 2026
Nurix aims for Accelerated Approval submission for DAYBreak CLL-201 Phase 2 study
Company continues enrollment in NX-5948-301 Phase 1a/1b trial of bexobrutideg in patients with relapsed or refractory B cell malignancies
Result Drivers
DAYBREAK INITIATION - Nurix initiated DAYBreak pivotal Phase 2 single-arm study for bexobrutideg in relapsed/refractory CLL, supported by compelling Phase 1 data
PHASE 1 RESULTS - Bexobrutideg showed 83% objective response rate with median progression-free survival of 22.1 months and median duration of response of 20.1 months across all doses tested
IRAK4 DEGRADER - Preclinical data for IRAK4 degrader Program showed potential efficacy in autoimmune diseases, supporting further development
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income | -$78.22 mln | ||
Q4 Income from Operations | -$83.10 mln | ||
Q4 Operating Expenses | $96.67 mln | ||
Q4 Pretax Profit | -$78.22 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Nurix Therapeutics Inc is $30.00, about 54.6% above its January 27 closing price of $19.41
Press Release: ID:nGNX4HZ53X
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)